The comparison of blood glucose profile of diabetic patients who change Insulin Glargine to Insulin Degludec as basal insulin.
Phase 4
Recruiting
- Conditions
- Diabetes
- Registration Number
- JPRN-UMIN000009627
- Lead Sponsor
- Diabetes Therapeutics and Research Center, The University of Tokushima
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients who cannot record their blood glucose results. 2. Patients who cannot come to the clinic regularly. 3. Patients who are not allowed to keep good blood glucose management. 4. Patients who are considered tobe inappropriate for this trial by the physician.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Hypoglycemia frequency and insulin degludec requirement during 2 months after switching from insulin glargine.
- Secondary Outcome Measures
Name Time Method Body weight change, clinical parameters, and other side effects 2 months after switching from insulin glargine.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms differentiate Insulin Degludec from Insulin Glargine in glucose regulation for diabetes?
How does switching from Insulin Glargine to Insulin Degludec affect HbA1c and hypoglycemia rates in type 2 diabetes patients?
What biomarkers are associated with optimal response to Insulin Degludec in basal insulin therapy for diabetes mellitus?
What are the long-term adverse events of Insulin Degludec compared to Insulin Glargine in clinical practice for diabetes management?
How do ultra-long-acting insulins like Insulin Degludec compare to other GLP-1 receptor agonists in managing type 2 diabetes?